UK government has set up a new organization to replace Public Health England.
The United Kingdom government has set up a new organization, the National Institute for Health Protection (NIHP), which will replace Public Health England(PHE) and will focus onpublic health protection and infectious disease capability.
According to an August 18, 2020 press release, the NIHP will be formalized and operational from spring 2021, although works will commence immediately in the advancement of the UK’s response to the COVID-19 pandemic. Immediate work will include bringing together PHE and the National Health Service’s Test and Trace, as well as the analytical capability of the Joint Biosecurity Centre under a single leadership team.
Responding to the formation of the new organization, Richard Torbett, chief executive of the Association of the British Pharmaceutical Industry, said in a press release, “PHE has played a critical role during the pandemic, but more widely in delivering important initiatives on disease prevention and public health. Our members have worked closely with PHE across many areas; from our world-leading vaccination programs to diabetes prevention, through to critical work on antimicrobial resistance. Preventative healthcare should be front and center of plans for the NHS post COVID-19. It’s important we understand how the wider work on prevention and public health will be taken forward, where responsibility and accountability will sit, and how the new organization will work with health partners.”
Steve Bates OBE, CEO of the UK BioIndustry Association issued a comment on the formation of the NIHP in another press release. He said, “UK life science companies look forward to working with the NIHP on its vital mission. If the UK is to successfully bring on new technologies and have the ability to scale up at pace it’s imperative to consider the incentives for, and desired capacity within, the UK life science industry for the long term, which will compliment and work alongside the newly announced Institute and its world leading scientists. The UK’s groundbreaking, innovative companies are already working on COVID-19 solutions in partnership with the public sector—successfully embedding this culture for the long term will be a key for the country’s response to future threats and the NIHP’s success.”
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.